b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29517945</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>31</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>31</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1744-5078</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>27</Volume>\n                    <Issue>4</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Ocular immunology and inflammation</Title>\n                <ISOAbbreviation>Ocul. Immunol. Inflamm.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Management of Ocular Cicatricial Pemphigoid with Intravenous Immunoglobulin Monotherapy.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>636-642</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/09273948.2018.1433302</ELocationID>\n            <Abstract>\n                <AbstractText><i>Purpose</i>: To assess the long-term efficacy and safety of IVIg monotherapy in patients with recalcitrant ocular cicatricial pemphigoid (OCP). <i>Methods</i>: A chart review of all OCP patients seen at the Massachusetts Eye Research and Surgery Institution (MERSI) between 2005 and 2015 was completed. Stage was graded by using the Foster grading system. IVIg infusion was 2g/kg/cycle administered in 3 consecutive days monthly. <i>Results</i>: Of 512 OCP patients, 17 patients (34 eyes) treated with IVIg monotherapy were identified. Seven were female and ten were male. The average age at diagnosis was 60.7-year-old. The follow up time ranged from 12 to 140 months. Twenty-six eyes (76.5%) achieved remission. Nine remission eyes received cataract surgeries, and 2 of them had relapse (22.2%). The other 17 eyes did not undergo ocular surgery and remained in remission. IVIg monotherapy showed high efficacy in stage 1 OCP (7/7, 100%). Ocular surgery can be associated with OCP relapse (Table 2). <i>Conclusions</i>: IVIg monotherapy is an effective and safe therapy in patients with recalcitrant OCP. Ocular surgery can be associated with OCP relapse.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ma</LastName>\n                    <ForeName>Lina</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>You</LastName>\n                    <ForeName>Caiyun</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>c Department of Ophthalmology , Tianjin Medical University General Hospital , Tianjin , China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hernandez</LastName>\n                    <ForeName>Mikhail</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Maleki</LastName>\n                    <ForeName>Arash</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lasave</LastName>\n                    <ForeName>Andres</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schmidt</LastName>\n                    <ForeName>Alexander</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Stephenson</LastName>\n                    <ForeName>Andrew</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Thongzen</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Anesi</LastName>\n                    <ForeName>Stephen</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Foster</LastName>\n                    <ForeName>C Stephen</ForeName>\n                    <Initials>CS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Massachusetts Eye Research and Surgery Institution , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>d Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>03</Month>\n                <Day>08</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Ocul Immunol Inflamm</MedlineTA>\n            <NlmUniqueID>9312169</NlmUniqueID>\n            <ISSNLinking>0927-3948</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010390" MajorTopicYN="N">Pemphigoid, Benign Mucous Membrane</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014792" MajorTopicYN="Y">Visual Acuity</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Intravenous Immunoglobulin monotherapy</Keyword>\n            <Keyword MajorTopicYN="N">Ocular Cicatricial Pemphigoid</Keyword>\n            <Keyword MajorTopicYN="N">relapsing</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>1</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>3</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29517945</ArticleId>\n            <ArticleId IdType="doi">10.1080/09273948.2018.1433302</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'